Bioavailability of Spermidine in Healthy Males

NCT06017219 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-08-30

No results posted yet for this study

Summary

To evaluate in healthy males the safety of two doses of spermidine as assessed by occurrence of any Adverse Events/Serious adverse events.

Conditions

  • Healthy Subjects

Interventions

DIETARY_SUPPLEMENT

spermidine

spermidine

Sponsors & Collaborators

  • Chrysea Labs Lda

    lead INDUSTRY

Principal Investigators

  • Dr Patrick Keohane · Chrysea Labs

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2023-10-15
Completion
2024-12-14

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06017219 on ClinicalTrials.gov